Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Albany Molecular Research Inc. has reached an agreement with New River Pharmaceuticals under which it will contract manufacture the active pharmaceutical ingredient in New River's NRP104, a treatment for attention deficit hyperactivity disorder currently under FDA review. New River collaborated with Shire on development of the compound and has a commercialization agreement with Shire as well.
This article has been sent to the following recipient: